Abstract 431P
Background
Breast cancer survivors (BCS) often experience cancer-related fatigue (CRF), a distressing condition which does not have an effective standardised pharmacological intervention. Xiang Bei Yangrong Tang (XBYRT), a modified herbal traditional Chinese medicine (TCM) decoction, is formulated for the management of CRF in BCS. In this in vitro study, we evaluated the herb-enzyme inhibition for 9 of the herbal TCMs from the XBYRT formulation, on CYP2D6 activity.
Methods
The XBYRT herbal components evaluated were Radix Astragaliseu Hedysari, Radix Codonopsis Pilosulae, Rhizoma Atractylodis Macrocephalae, Poria cocos, Radix Paeoniae Alba, Fructus Ligustri Lucidi, Rhizoma Cyperi, Radix Polygalae and Bulbus Fritillariae Thunbergii. Varying concentrations of the herbal TCMs were assayed for herb-enzyme inhibition using the Vivid P450 CYP2D6 assay kit. The percentage inhibition for the maximum XBYRT concentration and the half maximal inhibitory concentrations (IC50) were determined. The maximum XBYRT concentration was calculated based on the total dosage of herbal components consumed, without accounting for first pass metabolism. The IC50 was calculated using the non-linear regression from GraphPad Prism 5.
Results
Assayed at the maximum XBYRT concentration, herbal components exhibiting the highest inhibition levels were Radix Codonopsis Pilosulae (56.8%), Poris cocos (45.0%), Fructus Ligustri Lucidi (42.9%) and Radix Paeoniae Alba (35.5%). The IC50 values of these four herbal components were 481µg/ml, 572 µg/ml, 447 µg/ml and 475 µg/ml respectively. The other 5 herbal components exhibited <30% inhibition at the maximum XBYRT concentrations.
Conclusions
Components of XBYRT display potential CYP2D6 enzymatic inhibition activities. Hence, caution should be taken with the concomitant usage of XBYRT with drugs that are CYP2D6 substrates such as tamoxifen. In vivo and clinical studies are required to ascertain the actual effects of these herbal components on drug metabolism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Health Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract